Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Head & Neck 1Gastrointestinal 1

Conditions

Nasopharyngeal Carcinoma 3Epstein-Barr Virus Infections 2Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Multiple Acyl Coenzyme A Dehydrogenase Deficiency 1Lymphoproliferative Disorders 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 5epacadostat 2Thiotepa 2Nonlinear Optical Microscopy 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Filgrastim 2Cytological Techniques 2Cyclophosphamide 2Biopsy, Fine-Needle 2Biopsy 2vocimagene amiretrorepvec 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1spartalizumab 1sapanisertib 1romidepsin 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1larotrectinib 1ipatasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Valganciclovir × Head & Neck × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡